Membrane-type matrix metalloproteinases: expression, roles in metastatic prostate cancer progression and opportunities for drug targeting

Abstract

The membrane-type matrix metalloproteinases (MT-MMPs), an important subgroup of the wider MMP family, demonstrate widespread expression in multiple tumor types, and play key roles in cancer growth, migration, invasion and metastasis. Despite a large body of published research, relatively little information exists regarding evidence for MT-MMP expression and function in metastatic prostate cancer. This review provides an appraisal of the literature describing gene and protein expression in prostate cancer cells and clinical tissue, summarises the evidence for roles in prostate cancer progression, and examines the data relating to MT-MMP function in the development of bone metastases. Finally, the therapeutic potential of targeting MT-MMPs is considered. While MT-MMP inhibition presents a significant challenge, utilisation of MT-MMP expression and proteolytic capacity in prostate tumors is an attractive drug development opportunity.

Keywords

Matrix metalloproteinase / membrane-type / metastasis / prostate cancer / microenvironment

References

[1] Gialeli C,Karamanos NK.Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting..FEBS J2011;278:16-27

[2] Vandenbroucke RE.Is there new hope for therapeutic matrix metalloproteinase inhibition?.Nat Rev Drug Discov2014;13:904-27

[3] Choi KY,Lee S.Protease-activated drug development..Theranostics2012;2:156-78 PMCID:PMC3296471

[4] Law B.Proteolysis: a biological process adapted in drug delivery, therapy, and imaging..Bioconjug Chem2009;20:1683-95

[5] Atkinson JM,Gill JH.Tumour endoproteases: the cutting edge of cancer drug delivery?.Br J Pharmacol2008;153:1344-52 PMCID:PMC2437906

[6] Itoh Y.Membrane-type matrix metalloproteinases: their functions and regulations..Matrix Biol2015;44-46:207-23

[7] Gong Y,Oh WK.Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer progression..Cancers2014;6:1298-327 PMCID:PMC4190542

[8] Daja MM,Zhao Z,Russell PJ.Characterization of expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in prostate cancer cell lines..Prostate Cancer Prostatic Dis2003;6:15-26

[9] Iizumi T,Kanoh S,Koiso K.Establishment of a new prostatic carcinoma cell line (TSU-Pr1)..J Urol1987;137:1304-6

[10] Nagakawa O,Yamaura T,Murata J,Saiki I.Expression of membrane-type 1 matrix metalloproteinase (MT1-MMP) on prostate cancer cell lines..Cancer Lett2000;155:173-9

[11] Jung M,Keyszer G,Kristiansen G,Loening SA.mRNA expression of the five membrane-type matrix metalloproteinases MT1-MT5 in human prostatic cell lines and their down-regulation in human malignant prostatic tissue..Prostate2003;55:89-98

[12] Delassus GS,Hoang S.Many new down- and up-regulatory signaling pathways, from known cancer progression suppressors to matrix metalloproteinases, differ widely in cells of various cancers..J Cell Physiol2010;224:549-58

[13] Sroka IC,Bowden GT.Membrane-type 1 matrix metalloproteinase is regulated by sp1 through the differential activation of AKT, JNK, and ERK pathways in human prostate tumor cells..Neoplasia2007;9:406-17 PMCID:PMC1877982

[14] Jennbacken K,Welen K,Damber JE.Prostate cancer progression into androgen independency is associated with alterations in cell adhesion and invasivity..Prostate2006;66:1631-40

[15] Gustavsson H,Damber JE.Transition of an androgen-dependent human prostate cancer cell line into an androgen-independent subline is associated with increased angiogenesis..Prostate2005;62:364-73

[16] Coulson-Thomas VJ,Coulson-Thomas YM,Tersariol IL,Toma L.Fibroblast and prostate tumor cell cross-talk: fibroblast differentiation, TGF-beta, and extracellular matrix down-regulation..Exp Cell Res2010;316:3207-26

[17] Trudel D,Meyer F,Tetu B.Membrane-type-1 matrix metalloproteinase, matrix metalloproteinase 2, and tissue inhibitor of matrix proteinase 2 in prostate cancer: identification of patients with poor prognosis by immunohistochemistry..Hum Pathol2008;39:731-9

[18] Paterson RF,MacLennan GT,Pan CX,Moore CR,Koch MO,Cheng L.Molecular genetic alterations in the laser-capture-microdissected stroma adjacent to bladder carcinoma..Cancer2003;98:1830-6

[19] Neuhaus J,Mannello F,Ganzer R.Protease expression levels in prostate cancer tissue can explain prostate cancer-associated seminal biomarkers-an explorative concept study..Int J Mol Sci2017;18:E976 PMCID:PMC5454889

[20] Cardillo MR,Gentile V.Quantitative immunohistochemical and in situ hybridization analysis of metalloproteinases in prostate cancer..Anticancer Res2006;26:973-82

[21] Reis ST,Iscaife A,Dip N,Guimaraes VR,Nahas WC,Leite KR.Loss of TIMP-1 immune expression and tumor recurrence in localized prostate cancer..Int Braz J Urol2015;41:1088-95 PMCID:PMC4756933

[22] Arpino V,Gill SE.The role of TIMPs in regulation of extracellular matrix proteolysis..Matrix Biol2015;44-46:247-54

[23] Reis ST,Pontes-Junior J,Dall'Oglio MF,Cruz JA,Srougi M.Underexpression of MMP-2 and its regulators, TIMP2, MT1-MMP and IL-8, is associated with prostate cancer..Int Braz J Urol2012;38:167-74

[24] Upadhyay J,Nemeth JA,Cummings GD,Sakr W,Cher ML.Membrane type 1-matrix metalloproteinase (MT1-MMP) and MMP-2 immunolocalization in human prostate: change in cellular localization associated with high-grade prostatic intraepithelial neoplasia..Clin Cancer Res1999;5:4105-10

[25] Sroka IC,Nagle RB.Differential localization of MT1-MMP in human prostate cancer tissue: role of IGF-1R in MT1-MMP expression..Prostate2008;68:463-76

[26] Riddick AC,Pennington CJ,Nuttall RK,Sethia KK,Collins AT,Ball RY.Identification of degradome components associated with prostate cancer progression by expression analysis of human prostatic tissues..Br J Cancer2005;92:2171-80 PMCID:PMC2361819

[27] Kessenbrock K,Werb Z.Matrix metalloproteinases: regulators of the tumor microenvironment..Cell2010;141:52-67 PMCID:PMC2862057

[28] Sounni NE,Host L.MT-MMPS as regulators of vessel stability associated with angiogenesis..Front Pharmacol2011;2:111 PMCID:PMC3108474

[29] Larue L.Epithelial-mesenchymal transition in development and cancer: role of phosphatidylinositol 3' kinase/AKT pathways..Oncogene2005;24:7443-54

[30] Cao J,Richman O,Kozarekar P.Membrane type 1 matrix metalloproteinase induces epithelial-to-mesenchymal transition in prostate cancer..J Biol Chem2008;283:6232-40

[31] Dissanayake SK,Johnson CE,Leotlela PD,Shah KV,Rosenthal DT,Jiang Y,Taub DD,Moon RT,Weeraratna AT.The Wnt5A/protein kinase C pathway mediates motility in melanoma cells via the inhibition of metastasis suppressors and initiation of an epithelial to mesenchymal transition..J Biol Chem2007;282:17259-71 PMCID:PMC2263117

[32] Bair EL,McDaniel K,Cress AE,Bowden GT.Membrane type 1 matrix metalloprotease cleaves laminin-10 and promotes prostate cancer cell migration..Neoplasia2005;7:380-9 PMCID:PMC1501144

[33] Udayakumar TS,Bair EL,Cress AE,Bowden GT.Membrane type-1-matrix metalloproteinase expressed by prostate carcinoma cells cleaves human laminin-5 beta3 chain and induces cell migration..Cancer Res2003;63:2292-9

[34] Wang X,Slaton JW,Ewing SL.Increased aggressiveness of human prostate PC-3 tumor cells expressing cell surface localized membrane type-1 matrix metalloproteinase (MT1-MMP)..J Androl2009;30:259-74

[35] Kogianni G,Waxman J.Endo180 expression with cofunctional partners MT1-MMP and uPAR-uPA is correlated with prostate cancer progression..Eur J Cancer2009;45:685-93

[36] Wang Y,Kong CZ,Zhu YY.Loss of P53 facilitates invasion and metastasis of prostate cancer cells..Mol Cell Biochem2013;384:121-7

[37] Sankpal UT,Abdelrahim M.Targeting Sp1 transcription factors in prostate cancer therapy..Med Chem2011;7:518-25

[38] Larsson O,Girnita L.Role of insulin-like growth factor 1 receptor signalling in cancer..Br J Cancer2005;92:2097-101 PMCID:PMC2361813

[39] Takahashi C,Horan TP,Maki M,Kitaura Y,Sasahara RM,Ikawa Y,Arakawa T.Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK..Proc Natl Acad Sci U S A1998;95:13221-6 PMCID:PMC23764

[40] Miki T,Okawa K,Noda M.The reversion-inducing cysteine-rich protein with Kazal motifs (RECK) interacts with membrane type 1 matrix metalloproteinase and CD13/aminopeptidase N and modulates their endocytic pathways..J Biol Chem2007;282:12341-52

[41] Rabien A,Erbersdobler A,Stephan C.RECK overexpression decreases invasive potential in prostate cancer cells..Prostate2012;72:948-54

[42] Filiz G.Reduction in tumour cell invasion by pigment epithelium-derived factor is mediated by membrane type-1 matrix metalloproteinase downregulation..Pharmazie2012;67:1010-4

[43] Qingyi Z,Junhong W,Weizhou H,Zeyu S.Unfavorable prognostic value of human PEDF decreased in high-grade prostatic intraepithelial neoplasia: a differential proteomics approach..Cancer Invest2009;27:794-801

[44] Tapia T,Chakrabarti R.LIM kinase1 modulates function of membrane type matrix metalloproteinase 1: implication in invasion of prostate cancer cells..Mol Cancer2011;10:6 PMCID:PMC3027192

[45] Sahadevan K,Leung HY,Robson CN.Selective over-expression of fibroblast growth factor receptors 1 and 4 in clinical prostate cancer..J Pathol2007;213:82-90

[46] Wang J,Cai Y,Ittmann MM.Altered fibroblast growth factor receptor 4 stability promotes prostate cancer progression..Neoplasia2008;10:847-56 PMCID:PMC2481572

[47] Sugiyama N,Meller P,Hyytiainen M,Kallioniemi O,Engelholm LH,Alitalo K,Lehti K.Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation..Cancer Res2010;70:7851-61

[48] Nguyen HL,Zarrabi K,Schmidt C.Oxidative stress and prostate cancer progression are elicited by membrane-type 1 matrix metalloproteinase..Mol Cancer Res2011;9:1305-18 PMCID:PMC4013752

[49] McCall P,Grimsley S,Edwards J.Is PTEN loss associated with clinical outcome measures in human prostate cancer?.Br J Cancer2008;99:1296-301 PMCID:PMC2570524

[50] Kim S,Mottillo EP,Ham YA,Kim CJ,Kim HR,Chen YQ.Posttranslational regulation of membrane type 1-matrix metalloproteinase (MT1-MMP) in mouse PTEN null prostate cancer cells: enhanced surface expression and differential O-glycosylation of MT1-MMP..Biochim Biophys Acta2010;1803:1287-97 PMCID:PMC2939279

[51] Ma XM.Molecular mechanisms of mTOR-mediated translational control..Nat Rev Mol Cell Biol2009;10:307-18

[52] Lin HY,Tseng TS,Chen DT.SNP-SNP interaction network in angiogenesis genes associated with prostate cancer aggressiveness..PLoS One2013;8:e59688 PMCID:PMC3618555

[53] Parray A,Kuriger JK,Rhim JS,Aburatani H,Koochekpour S.ROBO1, a tumor suppressor and critical molecular barrier for localized tumor cells to acquire invasive phenotype: study in African-American and Caucasian prostate cancer models..Int J Cancer2014;135:2493-506 PMCID:PMC4610361

[54] Di Lorenzo G,D'Armiento FP,Staibano S,D'Armiento M,De Placido S,Bianco AR.Expression of epidermal growth factor receptor correlates with disease relapse and progression to androgen-independence in human prostate cancer..Clin Cancer Res2002;8:3438-44

[55] Lin HY,Huang PY,Ochoa A,Mercante DE,Sellers TA,Cheng CH,Easton D,Amin Al Olama A,Muir K,Wiklund F,Haiman CA,Nordestgaard BG,Hamdy F,Khaw KT,Blot WJ,Maier C,Cybulski C,Brenner H,Batra J,Pandha H,Consortium P.SNP interaction pattern identifier (SIPI): an intensive search for SNP-SNP interaction patterns..Bioinformatics2017;33:822-33

[56] Gandaglia G,Briganti A,Schiffmann J,Graefen M,Sun M.Impact of the site of metastases on survival in patients with metastatic prostate cancer..Eur Urol2015;68:325-34

[57] Manca P,Iuliani M,De Lisi D,Del Re M,Tonini G.Determinants of bone specific metastasis in prostate cancer..Crit Rev Oncol Hematol2017;112:59-66

[58] Bonfil RD,Mobashery S.Are matrix metalloproteinases relevant therapeutic targets for prostate cancer bone metastasis?.Curr Oncol2008;15:188-92 PMCID:PMC2528310

[59] Holmbeck K,Caterina J,Kromer M,Mankani M,Poole AR,Ward JM.MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover..Cell1999;99:81-92

[60] Nemeth JA,Herzog M,Upadhyay J,Bhagat S,Fridman R.Matrix metalloproteinase activity, bone matrix turnover, and tumor cell proliferation in prostate cancer bone metastasis..J Natl Cancer Inst2002;94:17-25

[61] Bonfil RD,Trindade Filho JC,Osenkowski P,Yamamoto H,Zhao H,Vessella RL,Cher ML.Prostate cancer-associated membrane type 1-matrix metalloproteinase: a pivotal role in bone response and intraosseous tumor growth..Am J Pathol2007;170:2100-11 PMCID:PMC1899437

[62] Sabbota AL,Zhe X,Bonfil RD.Shedding of RANKL by tumor-associated MT1-MMP activates Src-dependent prostate cancer cell migration..Cancer Res2010;70:5558-66 PMCID:PMC2896434

[63] Huang CF,Chu K,Lee YC,Kim SM,Wu FL,Yu-Lee LY.Cadherin-11 increases migration and invasion of prostate cancer cells and enhances their interaction with osteoblasts..Cancer Res2010;70:4580-9 PMCID:PMC2923552

[64] Kawaguchi J,Hoshi K,Takeshita S,Ozawa H,Chisaka O.Targeted disruption of cadherin-11 leads to a reduction in bone density in calvaria and long bone metaphyses..J Bone Miner Res2001;16:1265-71

[65] Cathcart J,Cao J.Targeting matrix metalloproteinases in cancer: bringing new life to old ideas..Genes Dis2015;2:26-34 PMCID:PMC4474140

[66] Vartak DG.Matrix metalloproteases: underutilized targets for drug delivery..J Drug Target2007;15:1-20 PMCID:PMC3782085

[67] Deryugina EI.Tumor angiogenesis: MMP-mediated induction of intravasation- and metastasis-sustaining neovasculature..Matrix Biol2015;44-46:94-112 PMCID:PMC5079283

[68] Lafleur MA,Knauper V,Edwards DR.Endothelial tubulogenesis within fibrin gels specifically requires the activity of membrane-type-matrix metalloproteinases (MT-MMPs)..J Cell Sci2002;115:3427-38

[69] Zawilska JB,Olejniczak AB.Prodrugs: a challenge for the drug development..Pharmacol Rep2013;65:1-14

[70] Barve A,Cheng K.Prostate cancer relevant antigens and enzymes for targeted drug delivery..J Control Release2014;187:118-32 PMCID:PMC4079732

[71] Bhattacharyya B,Gupta S.Anti-mitotic activity of colchicine and the structural basis for its interaction with tubulin..Med Res Rev2008;28:155-83

[72] Atkinson JM,Edwards DR,Siller CS,Bibby MC,Loadman PM.Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases..Cancer Res2010;70:6902-12 PMCID:PMC2933508

[73] Gill JH,Shnyder SD,Atkinson JM,Patterson LH.Tumor-targeted prodrug ICT2588 demonstrates therapeutic activity against solid tumors and reduced potential for cardiovascular toxicity..Mol Pharm2014;11:1294-300

[74] Loadman PM,Mitchell A,Spencer JA,Gill JH.Improved delivery of paclitaxel to prostate tumors: a membrane-type matrix metalloproteinase (MT-MMP)-targeted approach..Cancer Res2016;76:2054

[75] Graff JN.Should docetaxel be administered earlier in prostate cancer therapy?.Expert Rev Anticancer Ther2015;15:977-9

[76] James ND,Clarke NW,De Bono JS,Hetherington J,Jones RJ,Lester JF,Parker CC,Ritchie AW,Strebel RT,Mason MD.Survival with newly diagnosed metastatic prostate cancer in the "docetaxel rra": data from 917 Patients in the control arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019)..Eur Urol2015;67:1028-38

[77] James ND,Clarke NW,Dearnaley DP,Ritchie AW,Russell JM,de Bono J,Jones RJ,Amos C,Millman R,Beesley S,Brock S,Chakraborti P,Cook A,Gale J,Graham JD,Hughes R,McKinna F,O'Sullivan JM,Peedell C,Robinson AJ,Srinivasan R,Sundar S,Tsang D,Parmar MK.Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial..Lancet2016;387:1163-77

[78] Bonfil RD.The role of proteolytic enzymes in metastatic bone disease..IBMS BoneKEy2011;8:16-36